SBC Medical Group Holdings Announces its Purchase of Bitcoin — Neutral
SBC Business Wire — February 12, 2025TOKYO--(BUSINESS WIRE)-- #InvestorRelations--SBC Medical today announced that it has made a decision to purchase Bitcoin (BTC), the world's most widely circulated cryptocurrency.

DMC Global Rejects Non-Binding Proposal from Steel Connect — Neutral
BOOM GlobeNewsWire — February 12, 2025Steel Connect proposal undervalues DMC and denies stockholders participation in the Company's emerging value creation opportunity

Down 50% In 8 Months, Is Crocs Stock A Buy Ahead Of Earnings? — Negative
CROX Seeking Alpha — February 12, 2025Crocs, Inc. stock has tumbled by nearly 50% since June 2024, underperforming industry peers and the broader stock market. Despite producing lackluster growth numbers in recent quarters, Crocs' strong free cash flow generation (optionality) and strategic investments in brand growth support long-term business potential. Wall Street analysts remain bullish on CROX, with a consensus price target implying ~50% upside and TQI's fair value estimate suggesting +102% potential.

Crown Crafts Announces Third Quarter Fiscal 2025 Financial Results — Neutral
CRWS GlobeNewsWire — February 12, 2025GONZALES, La. , Feb. 12, 2025 (GLOBE NEWSWIRE) -- Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) today reported results for the third quarter fiscal year 2025, which ended December 29, 2024.

Martin Marietta Reports Fourth-Quarter and Full-Year 2024 Results — Neutral
MLM GlobeNewsWire — February 12, 2025Earnings Growth and Margin Expansion Resumed in the Fourth Quarter Achieved Full-Year Records for Aggregates Revenues, Gross Profit and Unit Profitability Completed Aggregates Bolt-Ons in Florida, Southern California and Texas in the Fourth Quarter RALEIGH, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”), a leading national supplier of aggregates and heavy building materials, today reported results for the fourth quarter and year ended December 31, 2024.

Ryder Reports Fourth Quarter 2024 Results and Provides 2025 Outlook — Neutral
R Business Wire — February 12, 2025MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) reported results for the three months ended December 31 as follows: (In millions, except EPS) Earnings Before Taxes Earnings Diluted Earnings Per Share 2024 2023 2024 2023 2024 2023 Continuing operations (GAAP) $ 181 160 $ 135 124 $ 3.11 2.74 Comparable (non-GAAP) $ 199 172 $ 150 134 $ 3.45 2.95 Total and operating revenue for the three months ended December 31 were as follows: (In millions) Total.

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short — Neutral
BIIB CNBC — February 12, 2025Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.

Alpine Income Property Trust Announces Approval of New $10 Million Common Stock Repurchase Program — Neutral
PINE GlobeNewsWire — February 12, 2025WINTER PARK, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that its Board of Directors approved a new common stock repurchase program (the “Program”). Under the Program, the Company may acquire shares of the Company's common stock, $0.01 par value per share (“Common Stock”), in the open market, from time to time, in block trades, or otherwise, for a total purchase price of up to $10,000,000. The Program does not require the Company to repurchase any dollar amount or number of shares of Common Stock and may be suspended or …

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 — Neutral
ACRS GlobeNewsWire — February 12, 2025- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.

Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook — Neutral
EXC Business Wire — February 12, 2025CHICAGO--(BUSINESS WIRE)--Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024. "I am pleased to announce Exelon has delivered against our financial goals for the third straight year since becoming a transmission and delivery-only company, and we delivered top quartile performance across all our local energy companies, with ComEd and Pepco Holdings in the top decile," said Exelon President and Chief Executive Officer Calvin Butler. "Our.

Restaurant Brands reports 2.5% same-store sales growth, fueled by Burger King and Popeyes — Positive
QSR CNBC — February 12, 2025Restaurant Brands International reported quarterly adjusted earnings per share of 81 cents and revenue of $2.3 billion. Burger King's and Popeyes' U.S. restaurants outperformed Wall Street's expectations.

Alphabet Is Closing The Gap With Google Cloud — Positive
GOOG GOOGL Seeking Alpha — February 12, 2025Alphabet's Google Cloud grew 30% YoY in Q4'24, with operating margins rising to 17.51%, driven by strong AI and developer adoption. Management plans to deploy $75B in eFY25 to boost compute capacity, supporting further growth in Google Cloud and AI initiatives. Despite capacity constraints, Alphabet's AI tools like Gemini 2.0 and Vertex AI are seeing significant adoption, enhancing internal efficiencies with AI agents automating processes.

Drugmaker Biogen forecasts 2025 profit below expectations — Negative
BIIB Reuters — February 12, 2025Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.

The AI Trade Is Far From Dead. TE Connectivity Goes All-In. — Positive
TEL Barrons — February 12, 2025TE Connectivity is buying electrical products maker Richards Manufacturing for $2.3 billion.

Transocean to Report Q4 Earnings: What's in the Offing for the Stock? — Positive
RIG Zacks Investment Research — February 12, 2025RIG is expected to report higher revenues from the year-ago period's level. Despite this revenue growth, it is expected to have faced increased costs and expenses.

Best Value Stocks to Buy for February 12th — Positive
MRC Zacks Investment Research — February 12, 2025MRC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 12, 2025.

Redwire Awarded Contract to Lead Study for the European Space Agency's Next Dark Matter Mission — Neutral
RDW Business Wire — February 12, 2025JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today it has been awarded a study contract from the European Space Agency (ESA) to develop the preliminary spacecraft design for an upcoming astrophysics mission that will image faint galaxies in the nearby universe and provide insight into the nature of dark matter. Redwire's wholly owned Belgian subsidiary, Redwire Space NV, has been awarded o.

Barrick Delivers Strong Year-End Performance While Advancing Key Growth Projects — Neutral
GOLD GlobeNewsWire — February 12, 2025Fourth Quarter and Full Year 2024 Results All amounts expressed in US dollars TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) delivered a strong performance in Q4, increasing gold production by 15% and copper production by 33% over Q3 to meet its annual guidance for the year. Additionally, gold cost of sales1 and total cash costs2 for the quarter were reduced by 3% and 5%, respectively.

Radware Reports Fourth Quarter and Full Year 2024 Financial Results — Neutral
RDWR GlobeNewsWire — February 12, 2025Fourth Quarter 2024 Financial Results and Highlights

Patria Reports Fourth Quarter & Full Year 2024 Earnings Results — Neutral
PAX GlobeNewsWire — February 12, 2025GRAND CAYMAN, Cayman Islands, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Patria (Nasdaq:PAX) reported today its unaudited results for the fourth quarter and full year ended December 31, 2024. The full detailed presentation of Patria's fourth quarter and full year 2024 results can be accessed on the Shareholders section of Patria's website at https://ir.patria.com/.
